## **Special Issue**

## Novel Promising Molecular Diagnostic and Prognostic Tools in Malignant Tumors

### Message from the Guest Editor

Recent research continues to shed light on the underlying molecular mechanisms contributing to cancer pathogenesis. Tumor molecular profiling paved the way for new, personalized, and effective therapies, greatly contributing to patients' clinical outcomes. The application of molecular techniques in the field of diagnosis has the potential to reshape the current approach to disease detection and management. Novel, sensitive molecular markers, often obtained through non-invasive procedures, offer the possibility of mass screening, leading to early disease diagnosis. Tumor molecular subtype identification aids in disease severity and progress determination, designating further diagnostic and treatment intervention needs and defining prognosis. In this Special Issue, we welcome research works regarding the implementation of molecular techniques in the risk assessment, early diagnosis, molecular typing, biological behavior prediction, prognosis evaluation and drug screening for malignant tumors.

### Guest Editor

Prof. Dr. Stamatios E. Theocharis First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Goudi, Athens, Greece

### Deadline for manuscript submissions

closed (30 April 2022)



## **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/82131

Diagnostics Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 diagnostics@mdpi.com

mdpi.com/journal/ diagnostics





# **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



diagnostics



## About the Journal

## Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

### Editor-in-Chief

#### Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

## **Author Benefits**

## High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).